- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00002041
Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients
October 1, 2007 updated by: Bristol-Myers Squibb
To determine the appropriate duration of amphotericin B therapy for Candida esophagitis.
To compare the effectiveness of two different amphotericin B doses in the treatment of biopsy-proven Candida esophagitis.
To determine if low-dose amphotericin B is less toxic than standard dose therapy during a limited treatment period.
To evaluate pharmacokinetic and pharmacodynamic parameters of the two different dosing regimens.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Princeton, New Jersey, United States, 085434000
- Bristol - Myers Squibb Co
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Exclusion Criteria
Co-existing Condition:
Patients with histological or clinical (skin rash, cotton wool exudates, Candida endophthalmitis, etc.) evidence of disseminated candidiasis are excluded.
Concurrent Medication:
Excluded:
- Systemic administration of amphotericin B for a proven or suspected systemic fungal infection.
Patients with the following are excluded:
- Documented Candida fungemia.
- Histological or clinical (skin rash, cotton wool exudates, Candida endophthalmitis, etc.) evidence of disseminated candidiasis.
- Systemic administration of amphotericin B for a proven or suspected systemic fungal infection.
- Patient refusal to enter study.
Patient must be an immunosuppressed host, with biopsy-proven Candida esophagitis.
- Patients with polymicrobial esophagitis will be included as long as Candida esophagitis is documented by esophageal biopsy.
- Informed consent must be signed and obtained.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
November 2, 1999
First Submitted That Met QC Criteria
August 30, 2001
First Posted (Estimate)
August 31, 2001
Study Record Updates
Last Update Posted (Estimate)
October 2, 2007
Last Update Submitted That Met QC Criteria
October 1, 2007
Last Verified
October 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Infections
- Gastrointestinal Diseases
- Gastroenteritis
- Bacterial Infections and Mycoses
- Mycoses
- Esophageal Diseases
- Candidiasis
- Esophagitis
- Anti-Infective Agents
- Anti-Bacterial Agents
- Antifungal Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Amebicides
- Amphotericin B
- Liposomal amphotericin B
Other Study ID Numbers
- 001A
- 875-10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Amphotericin B
-
Bharat Serums and Vaccines LimitedMinistry of Science and TechnologyCompletedLeishmaniasis, VisceralIndia
-
Aurobindo Pharma LtdAxis Clinicals LimitedCompletedVisceral LeishmaniasisBangladesh, India
-
Astellas Pharma Global Development, Inc.TerminatedCandidiasisPhilippines, United States, Canada, Israel, Romania, Greece, Turkey, Brazil, Bulgaria, Colombia, Hungary, Ukraine
-
Banaras Hindu UniversityCompletedVisceral LeishmaniasisIndia
-
Southeast University, ChinaCompleted
-
LiposomeCompletedHIV Infections | Meningitis, CryptococcalUnited States
-
Peking Union Medical College HospitalRecruiting
-
Taiwan Liposome CompanyCompleted
-
European Organisation for Research and Treatment...CompletedCancerBelgium, Netherlands, Italy, Hungary, France, Spain, Germany, Israel, Czech Republic, United Arab Emirates, Sweden, Greece, Turkey, Portugal, Slovakia
-
Matinas BioPharma Nanotechnologies, Inc.CompletedCandidiasis, Chronic MucocutaneousUnited States